Background Most observational studies on direct oral anticoagulants (DOACs) used single
data sources with limited generalizability. This ARISTOPHANES (Anticoagulants for …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

Background: Clinical trials have shown direct oral anticoagulants (DOACs) are at least as
effective and safe as warfarin for risk of stroke/systemic embolism (S/SE) and major bleeding …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

In the pivotal randomized controlled trials (RCTs) for patients with atrial fibrillation, direct oral
anticoagulants (DOACs) had similar or even superior efficacy and safety compared with …

Background It remains unknown whether the comparative effectiveness and safety of direct
oral anticoagulants (DOACs) and warfarin differ across levels of stroke risk. We compared …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …

Abstract Background Direct oral anticoagulants (DOACs) have been proven to be effective
and safe for prevention of ischemic stroke and systemic embolism in patients with non …